Higher doses tested to halt dangerous seizures in newborn babies
NCT ID NCT05610085
Summary
This study aims to find the safest and most effective dose of the drug levetiracetam to control seizures in newborn babies. Researchers will test increasingly higher doses in up to 133 newborns who have mild to moderate seizures, comparing them to a standard treatment. The goal is to better control these dangerous seizures, which can harm a baby's developing brain, and improve long-term health outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Auckland City Hospital
RECRUITINGAuckland, Auckland, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Capital and Coast District Health Board, Te Whatu Ora, Health New Zealand
RECRUITINGWellington, Wellington Region, 6021, New Zealand
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Middlemore Hospital
RECRUITINGAuckland, Auckland, 1050, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Diego
RECRUITINGSan Diego, California, 92093, United States
Contact Email: •••••@•••••
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.